Legendary Silicon Valley venture group Kleiner Perkins Caufield & Byers — a player in the biotech arena — has outlined plans to raise $400 million for a new fund in a filing yesterday with the SEC.
That number may well just be a place holder for the final figure. CNBC reported a few weeks ago that Kleiner Perkins was raising two funds for a total of about $1.3 billion, quoting sources. About $800 million of that was being reserved for more mature companies while the rest would be startup oriented.
The high profile Beth Seidenberg, a former R&D exec who joined KPCB after a stint as CMO at Amgen, is listed in the filing, which was dispatched on Thursday. Her role as a VC player has put her on the boards of 3-V Biosciences, ARMO Biosciences, Breathe Technologies, FLX, Hixme, Kinsa, Mango Health, Practice Fusion, Progyny and True North; as well as three publicly traded companies: Atara Bio (ATRA), Epizyme (EPZM) and Tesaro (TSRO).
We’d ask her for a comment, but the venture firm is in a quiet period now, so we’ll save that for later.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.Free Subscription